A detailed history of New Edge Advisors, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 500 shares of SAVA stock, worth $1,345. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 500 -0.0%
Holding current value
$1,345
Previous $6,000 133.33%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$12.35 - $26.11 $3,705 - $7,833
300 Added 150.0%
500 $6,000
Q1 2024

May 14, 2024

BUY
$18.44 - $26.41 $2,766 - $3,961
150 Added 300.0%
200 $4,000
Q2 2023

Aug 14, 2023

SELL
$21.59 - $27.88 $8,636 - $11,152
-400 Reduced 88.89%
50 $1,000
Q4 2022

Feb 14, 2023

BUY
$27.82 - $44.16 $12,519 - $19,872
450 New
450 $13,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $108M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.